Ten years of change in clinical disease status and treatment in rheumatoid arthritis: Results based on standardized monitoring of patients in an ordinary outpatient clinic in southern Norway

Arthritis Research and Therapy

Volumn 17, Issue 1, 2015, Pages

  Haugeberg, Glenn ^a,b   Hansen, Inger Johanne Widding ^a   Soldal, Dag Magnar ^a   Sokka, Tuulikki ^c  

^a Hospital of Southern Norway Kristiansand   (Norway)

^b NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

^c JYVÄSKYLÄ CENTRAL HOSPITAL   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; ADALIMUMAB; C REACTIVE PROTEIN; CERTOLIZUMAB PEGOL; CYCLIC CITRULLINATED PEPTIDE ANTIBODY; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; GOLIMUMAB; HYDROXYCHLOROQUINE; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; PREDNISOLONE; PROTEIN ANTIBODY; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RHEUMATOID FACTOR; RITUXIMAB; SALAZOSULFAPYRIDINE; TOCILIZUMAB; ANTIRHEUMATIC AGENT; GLUCOCORTICOID;

ADULT; ARTHRALGIA; ARTICLE; CLINICAL DISEASE ACTIVITY INDEX; CONTROLLED STUDY; DEMOGRAPHY; DISEASE ACTIVITY; DISEASE ACTIVITY SCORE; DISEASE DURATION; ERYTHROCYTE SEDIMENTATION RATE; FATIGUE; HUMAN; MIDDLE AGED; MORNING STIFFNESS; NORWAY; OUTCOME ASSESSMENT; OUTPATIENT CARE; PATIENT MONITORING; REMISSION; RHEUMATOID ARTHRITIS; SIMPLIFIED DISEASE ACTIVITY INDEX; AGED; ARTHRITIS, RHEUMATOID; DISEASE COURSE; FEMALE; FOLLOW UP; MALE; OUTPATIENT DEPARTMENT; SEVERITY OF ILLNESS INDEX; STATISTICS AND NUMERICAL DATA; TIME FACTOR; TRENDS; VERY ELDERLY;

AGED; AGED, 80 AND OVER; AMBULATORY CARE FACILITIES; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; GLUCOCORTICOIDS; HUMANS; MALE; MIDDLE AGED; NORWAY; OUTCOME ASSESSMENT (HEALTH CARE); PREDNISOLONE; REMISSION INDUCTION; SEVERITY OF ILLNESS INDEX; TIME FACTORS;

EID: 84939495829     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/s13075-015-0716-0     Document Type: Article

References (32)

1. Pincus T, Sokka T, Kavanaugh A. Relative versus absolute goals of therapies for RA: ACR 20 or ACR 50 responses versus target values for "near remission" of DAS or single measures. Clin Exp Rheumatol. 2004;22(5 Suppl 35):S50-6.
2. Sokka T, Hannonen P, Mäkinen H. Remission: a realistic goal in rheumatoid arthritis? Int J Clin Rheumatol. 2011;6:643-7.
3. Smolen JS, Aletaha D, Koeller M, Weisman MH, Emery P. New therapies for treatment of rheumatoid arthritis. Lancet. 2007;370:1861-74.
4. Sokka T, Pincus T. Rheumatoid arthritis: strategy more important than agent. Lancet. 2009;374:430-2.
5. Möttönen T, Hannonen P, Leirisalo-Repo M, Nissilä M, Kautiainen H, Korpela M, et al. Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: a randomised trial. Lancet. 1999;353:1568-73.
6. Smolen JS, Aletaha D, Bijlsma JW, Breedveld FC, Boumpas D, Burmester G, et al. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis. 2010;69:631-7.
7. Pincus T, Wolfe F. Patient questionnaires for clinical research and improved standard patient care: is it better to have 80 % of the information in 100 % of patients or 100 % of the information in 5 % of patients? J Rheumatol. 2005;32:575-7.
8. Smolen JS, Aletaha D. Patients with rheumatoid arthritis in clinical care. Ann Rheum Dis. 2004;63:221-5.
9. Silman A, Klareskog L, Breedveld F, Bresnihan B, Maini R, Van Riel P, et al. Proposal to establish a register for the long term surveillance of adverse events in patients with rheumatic diseases exposed to biological agents: the EULAR Surveillance Register for Biological Compounds. Ann Rheum Dis. 2000;59:419-20.
10. Elkayam O, Pavelka K. Biologic registries in rheumatology: lessons learned and expectations for the future. Autoimmun Rev. 2012;12:329-36.
11. Kvien TK, Heiberg, Lie E, Kaufmann C, Mikkelsen K, Nordvåg BY, et al. A Norwegian DMARD register: prescriptions of DMARDs and biological agents to patients with inflammatory rheumatic diseases. Clin Exp Rheumatol. 2005;23(5 Suppl 39):S188-94.
12. Hetland ML. DANBIO-powerful research database and electronic patient record. Rheumatology (Oxford). 2011;50:69-77.
13. Sokka T, Haugeberg G, Pincus T. Assessment of quality of rheumatoid arthritis care requires joint count and/or patient questionnaire data not found in a usual medical record: examples from studies of premature mortality, changes in clinical status between 1985 and 2000, and a QUEST-RA global perspective. Clin Exp Rheumatol. 2007;25:86-97.
14. Olsen IC, Haavardsholm EA, Moholt E, Kvien TK, Lie E. NOR-DMARD data management: implementation of data capture from electronic health records. Clin Exp Rheumatol. 2014;85:158-62.
15. DiaGraphIT. GoTreatIT Rheuma software program. http://www.diagraphit.com/index.php?expand=24&show=24&topmenu_2=19 . Accessed 20 July 2015.
16. Pincus T, Summey JA, Soraci Jr SA, Wallston KA, Hummon NP. Assessment of patient satisfaction in activities of daily living using a modified Stanford Health Assessment Questionnaire. Arthritis Rheum. 1983;26:1346-53.
17. Prevoo ML, van 't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modified disease activity scores that include twenty-eight-joint counts: development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum. 1995;38:44-8.
18. Aletaha D, Smolen JS. The Simplified Disease Activity Index (SDAI) and Clinical Disease Activity Index (CDAI) to monitor patients in standard clinical care. Best Pract Res Clin Rheumatol. 2007;21:663-75.
19. van Gestel AM, Haagsma CJ, van Riel PL. Validation of rheumatoid arthritis improvement criteria that include simplified joint counts. Arthritis Rheum. 1998;41:1845-50.
20. Felson DT, Smolen JS, Wells G, Zhang B, van Tuyl LH, Funovits J, et al. American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Arthritis Rheum. 2011;63:573-86.
21. Grigor C, Capell H, Stirling A, McMahon AD, Lock P, Vallance R, et al. Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial. Lancet. 2004;364:263-9.
22. Rantalaiho V, Kautiainen H, Korpela M, Puolakka K, Blåfield H, Ilva K, et al. Physicians' adherence to tight control treatment strategy and combination DMARD therapy are additively important for reaching remission and maintaining working ability in early rheumatoid arthritis: a subanalysis of the FIN-RACo trial. Ann Rheum Dis. 2014;73:788-90.
23. Aga AB, Lie E, Uhlig T, Olsen IC, Wierød A, Kalstad S, et al. Time trends in disease activity, response and remission rates in rheumatoid arthritis during the past decade: results from the NOR-DMARD study 2000-2010. Ann Rheum Dis. 2015;74:381-8. doi: 10.1136/annrheumdis-2013-204020 .
24. Hetland ML, Lindegaard HM, Hansen A, Podenphant J, Unkerskov J, Ringsdal VS, et al. Do changes in prescription practice in patients with rheumatoid arthritis treated with biological agents affect treatment response and adherence to therapy? Results from the nationwide Danish DANBIO Registry. Ann Rheum Dis. 2008;67:1023-6.
25. Hyrich KL, Watson KD, Lunt M, Symmons DP, British Society for Rheumatology Biologics Register (BSRBR). Changes in disease characteristics and response rates among patients in the United Kingdom starting anti-tumour necrosis factor therapy for rheumatoid arthritis between 2001 and 2008. Rheumatology (Oxford). 2011;50:117-23.
26. Nell VP, Machold KP, Eberl G, Stamm TA, Uffmann M, Smolen JS. Benefit of very early referral and very early therapy with disease-modifying anti-rheumatic drugs in patients with early rheumatoid arthritis. Rheumatology (Oxford). 2004;43:906-14.
27. Lard LR, Visser H, Speyer I, vander Horst-Bruinsma IE, Zwinderman AH, Breedveld FC, et al. Early versus delayed treatment in patients with recent-onset rheumatoid arthritis: comparison of two cohorts who received different treatment strategies. Am J Med. 2001;111:446-51.
28. Jönsson B, Kobelt G, Smolen J. The burden of rheumatoid arthritis and access to treatment: uptake of new therapies. Eur J Health Econ. 2008;8 Suppl 2:S61-86.
29. Sokka T, Kautiainen H, Toloza S, Mäkinen H, Verstappen SM, Lund Hetland M, et al. QUEST-RA: quantitative clinical assessment of patients with rheumatoid arthritis seen in standard rheumatology care in 15 countries. Ann Rheum Dis. 2007;66:1491-6.
30. Sokka T, Haugeberg G, Asikainen J, Widding Hansen IJ, Kokko A, Rannio T, et al. Similar clinical outcomes in rheumatoid arthritis with more versus less expensive treatment strategies: observational data from two rheumatology clinics. Clin Exp Rheumatol. 2013;31:409-14.
31. Brown AK, Quinn MA, Karim Z, Conaghan PG, Peterfy CG, Hensor E, et al. Presence of significant synovitis in rheumatoid arthritis patients with disease-modifying antirheumatic drug-induced clinical remission: evidence from an imaging study may explain structural progression. Arthritis Rheum. 2006;54:3761-73.
32. Naranjo A, Toloza S, Guimaraes da Silveira I, Lazovskis J, Hetland ML, Hamoud H, et al. Smokers and non smokers with rheumatoid arthritis have similar clinical status: data from the multinational QUEST-RA database. Clin Exp Rheumatol. 2010;28:820-7.